The COMPLETE TAVR study is a clinical trial comparing two strategies for patients with severe aortic stenosis and concomitant coronary artery disease (CAD) undergoing transcatheter aortic valve replacement (TAVR). One group will receive complete revascularization with staged percutaneous coronary intervention (PCI) using drug-eluting stents, while the other group will receive only medical therapy. The trial aims to determine if PCI can reduce the risk of cardiovascular death, heart attacks, and hospitalizations compared to medical management alone.